News

November 8, 2011 – Boston Scientific reports clinical endpoint data from its PLATINUM Long Lesion trial, demonstrating excellent outcomes for the Promus Element everolimus-eluting platinum...

November 7, 2011 – Abbott announced the company's schedule of key data presentations at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, to be held Nov. 7 – 11...

The U.S. Food and Drug Administration (FDA) granted market clearance for the Xience Prime everolimus-eluting coronary stent system for the treatment of coronary artery disease. The stent uses the...

November 1, 2011 – Boston Scientific released the schedule of its major events and product-related clinical research for the Cardiovascular Research Foundation's (CRF) 23rd annual Transcatheter...

October 18, 2011 — Boston Scientific Corp. has begun a phased launch of its Promus Element everolimus-eluting platinum chromium coronary stent system in China. The launch campaign will be expanded...

A U.S. Food and Drug Administration (FDA) review panel has given its unanimous recommendation for the market approval of the Zilver PTX stent. It is the first device of its kind on several fronts...

October 5, 2009 – In a breakthrough development that could dramatically reduce the number of leg amputations and painful bypass graft surgeries performed annually on European patients, a first-of-...

January 20, 2011 – Drug-coated stents hold promise as a safe and lasting solution for the treatment of clogged leg arteries, suggest two-year results of the Zilver PTX Trial being presented at the...

October 7, 2011 — Biosensors has announced completion of its acquisition of JW Medical Systems Ltd. (JWMS), one of the top three suppliers of drug-eluting stents (DES) in China.

Abbott began enrolling U.S. patients in the EXCEL trial, which will compare the use of the Xience Prime or Xience V drug-eluting strents to coronary artery bypass graft (CABG) surgery for...

September 13, 2011 – An U.S. Food and Drug Administration’s (FDA) will discuss recommendations for Cook Medical Zilver PTX self-expanding drug-eluting peripheral stent at its Oct. 13, 2011,...

August 31, 2011 — Results of a recent randomized controlled study show the drug-eluting stent Xience V performs well in patients having primary percutaneous coronary intervention (PCI) for ST...

August 17, 2011 — OrbusNeich announced its Genous stent showed no significant difference in target vessel failure (TVF) rate at two years from the Taxus Liberte paclitaxel-eluting stent in...

August 9, 2011 — Boston Scientific Corp. said the U.S. Court of Appeals for the First Circuit has affirmed the dismissal of a securities fraud case in connection with the 2004 recall of one...

July 29, 2011 — Boston Scientific Corporation's board of directors has approved a five-year, $150 million investment to expand its commercial presence in China, one of the world's largest and...

July 27, 2011 – Micell Technologies Inc. announced that it has completed patient enrollment in its DESSOLVE II CE mark clinical study of the MiStent drug-eluting coronary stent system. The MiStent...

July 26, 2011 – The Resolute drug-eluting stent (DES) from Medtronic Inc. showed superiority to Boston Scientific Corp.’s Taxus DES on in-stent late lumen loss at eight months, the primary...

June 30, 2011 — Micell Technologies Inc. announced that it has completed its review of the scheduled four-month follow-up on the first 10 patients from the DESSOLVE I first-in-human trial of the...
Cordis announced it will cease production of the Cypher sirolimus-eluting stent, the first drug-eluting stent (DES) to secure U.S. Food and Drug Administration (FDA) approval, by the end of 2011. The...
June 3, 2011 – New long-term data from the DIVERGE study, presented at EuroPCR 2011, showed that the use of the Axxess drug-eluting stent (DES) for the treatment of complex coronary bifurcation...
May 25, 2011 – Boston Scientific Corp. today announced it received approval from the U.S. Food and Drug Administration (FDA) to market its 2.25 mm Promus everolimus-eluting coronary stent system for...
The U.S. Food and Drug Administration (FDA) cleared the Xience nano everolimus-eluting coronary stent system for the treatment of coronary artery disease in small vessels. The Xience nano, which is...
May 23, 2011 — Elixir Medical Corporation, a developer of product platforms combining state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE Mark for its...
May 23, 2011– A pooled analysis of the global Resolute clinical program presented today during a late-breaking clinical trials session at EuroPCR demonstrated the strong safety record of the Resolute...
May 20, 2011 - Boston Scientific Corporation today announced 12-month results from its PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25mm Promus...
May 20, 2011 – e-BioMatrix post-marketing surveillance (PMS) registry information presented at EuroPCR 2011 has confirmed that BioMatrix, Biosensors’ Biolimus A9-eluting stent system with abluminal...
May 16, 2011 – In a coronary stent patent lawsuit, a jury said Cordis owes Boston Scientific approximately $19.5 million.
May 11, 2011 - Micell Technologies announced that positive preclinical data will be presented at the EuroPCR conference regarding the MiStent Drug-Eluting Coronary Stent System (MiStent DES), an...

April 26, 2011 – The U.S. Food and Drug Administration (FDA) announced this week it cleared Boston Scientific’s Ion paclitaxel-eluting coronary stent system. 

The stent, available for...

April 9, 2011 - The Resolute zotarolimus-eluting stent using a new biocompatible polymer achieved a lower rate of restenosis and in-stent thrombosis compared to the Endeavor stent at 12 months in...

April 8, 2011 – In the largest randomized, multicenter trial to compare drug-eluting stents (DES) and bare-metal stents (BMS) placed in saphenous vein graft lesions, researchers found that DES led...

April 8, 2011 — A study from a South Korean research team found that angioplasty with a sirolimus-eluting stent was non-inferior to coronary artery bypass surgery (CABG) in patients with...

April 6, 2011 – One-year results from the pivotal PLATINUM Workhorse trial were presented at the American College of Cardiology (ACC) Scientific Session in New Orleans. The trial compared the...

April 6, 2011 – Results from a pooled patient-level analysis favored a next-generation paclitaxel-eluting stent. Data from the PERSEUS and TAXUS ATLAS trials compared Boston Scientific’s Ion...

March 21, 2011 - OrbusNeich today announced it filed a lawsuit in the Netherlands against a doctor and principal investigator of a trial examining OrbusNeich's Genous coronary stent.

February 21, 2011 – Two drug-eluting coronary stent systems have been launched in India. Boston Scientific’s Promus Element everolimus-eluting stent system and Taxus Element paclitaxel-eluting...

February 21, 2011 – The first patient has been enrolled the DESSOLVE II study to support CE mark for a coronary stent that uses a bioresorbable drug polymer. The MiStent drug-eluting coronary...

January 26, 2011 – Patient enrollment has begun in China for a trial evaluating the safety and effectiveness of a next-generation stent. The PLATINUM China clinical trial will look at the Promus...

January 24, 2011 – Patient enrollment was completed in the EVOLVE clinical trial, which is designed to assess the safety and performance of the Boston Scientific's fourth-generation Synergy...

January 20, 2011 – European CE mark approval was granted to expand the indication of Abbott’s Xience Prime everolimus-eluting coronary stent for the treatment of critical limb ischemia (CLI) or...

January 10, 2011 – European CE mark approval was announced today for the Abbott, Absorb drug-eluting bioresorbable coronary stent. It is the first bioresorbable stent to gain regulatory approval...

December 6, 2010 - A European court has struck a blow to Boston Scientific's alleged patent infringement case against OrbusNeich. The case is viewed by OrbusNeich as an unsuccessful retaliatory...

September 28, 2010 – Three-year follow-up data from the HORIZONS-AMI trial presented at Transcatheter Cardiovascular Therapeutics (TCT) 2010 last week continues to show marked improvement of...

September 24, 2010 – Drug-eluting stents are beneficial in treating symptomatic peripheral artery disease (PAD) in the femoropopliteal artery. Data from the ZILVER PTX trial demonstrate that...

September 24, 2010 - Two-year data from the SPIRIT IV trial show that everolimus-eluting stents demonstrated enhanced safety and efficacy in treating de novo native coronary artery lesions when...

September 23, 2010 - Results from the second stage of a trial studying a bioresorbable vascular scaffold were announced at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington...

September 23, 2010 - Results from a study evaluating the safety and clinical efficacy of the Promus Element everolimus-eluting coronary stent will be released at the Transcatheter Cardiovascular...

September 22, 2010 – Coronary artery disease, a leading cause of death and poor quality of life worldwide, can often complicate the daily practice of interventional cardiology. But new data from...

September 21, 2010 – A new drug-eluting stent system has received CE mark approval for diabetic patients and those experiencing a heart attack.

The PROMUS element everolimus-eluting stent...

September 20, 2010 – Patient enrollment has started in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir Medical’s novolimus-eluting coronary stent with bioabsorbable coating,...

September 14, 2010 – The latest clinical trial data for the Promus Element and Taxus Element coronary stents will be released during the Transcatheter Cardiovascular Therapeutics (TCT) scientific...

September 8. 2010 – Intravascular ultrasound (IVUS)-guided bifurcation stenting significantly reduced the four-year mortality in patients as compared to conventional angiographically guided...

September 7, 2010 – New analyses of subgroups from the SORT OUT III study provide detail on longer-term follow-up safety and efficacy outcomes in diabetics and patients with acute coronary...

September 1, 2010 - The results of follow-up tests undertaken ten years after the first patient was treated with a Cypher sirolimus-eluting coronary stent were presented at the European Society of...

September 1, 2010 - A new zotarolimus-eluting coronary stent using a biocompatible polymer gained CE mark and is being launched in Europe this week. The Medtronic Resolute Integrity Stent System...

In the world of endovascular devices, the rule is no longer one size fits all. The recent increase in the variety of stents for percutaneous coronary intervention (PCI) offers the physician of a...

August 24, 2010 – Optical coherence tomography (OCT) evaluation of a patient with anterior ST-elevation myocardial infarction (STEMI) who received two OrbusNeich Genous Bio-engineered R stents...

August 19, 2010 – The Cardiovascular Research Foundation recently announced the late-breaking trials and first report investigations being presented at the Transcatheter Cardiovascular...

August 3, 2010 — Patient enrollment began in the EVOLVE clinical trial, which is designed to assess the safety and performance of the Boston Scientific Synergy Coronary Stent (previously referred...

July 30, 2010 – A drug-eluting coronary bifurcation stent received CE mark this week for clinical use in Europe. The Axxess Biolimus A9-Eluting Coronary Bifurcation Stent System uses a...

June 11, 2010 – A new drug-eluting stent (DES) was launched this week in the European Union and other CE mark countries. The Taxus Element Paclitaxel-Eluting Coronary Stent System is Boston...

June 3, 2010 – Six-month data from the first 45 patients enrolled in the second stage of a trial for a bioresorbable stent demonstrated strong results. Abbott's bioresorbable vascular scaffold (...

May 27, 2010 – One-year data presented this week at EuroPCR in Paris confirms sustained clinical outcomes with Cook Medical's drug-eluting peripheral stent, Zilver PTX.

May 26, 2010 – In the constantly evolving battle for the best coronary stent, Boston Scientific said today it initiated the PLATINUM PLUS clinical trial, comparing its next-generation Promus...

May 26, 2010 – The 12-month study results for a drug-eluting stent that uses hundreds of tiny holes, filled with bioresorbable drug polymer to reduce tissue/polymer contact, demonstrated excellent...

May 25, 2010 – The highly anticipated first results of the RESOLUTE All Comers study were presented today during the late-breaking clinical trial session of the 2010 EuroPCR meeting in Paris. In...

May 25, 2010 – A self-expanding, drug-eluting stent (DES) that just gained CE mark clearance in Europe is designed to ensure optimal apposition in the initial hours and days after an acute...

May 12, 2010 – A paclitaxel-eluting coronary stent received CE mark approval for a specific indication to treat diabetic patients. The Taxus Element incorporates a platinum chromium alloy and a...

May 10, 2010 – Patients treated with the Zilver PTX drug-eluting peripheral stent maintained clinical improvement at two years, according to interim results from the Zilver PTX Global Registry....

May 7, 2010 – Findings from the SPIRIT IV trial, one of the largest randomized clinical trials comparing two drug eluting stents with 3,690 U.S.-based patients, were published this week in The New...

May 6, 2010 – Patients who can postpone noncardiac surgery for at least six weeks after receiving a coronary stent are less likely to suffer reduced blood flow to the heart, heart attack and death...

May 6, 2010 – After entered the Japanese drug-eluting stent market earlier this year, Abbott's Xience V and Boston Scientific's Promus stents picked up share from competitors Medtronic and Cordis...

May 3, 2010 – Excellent safety and clinical outcomes were shown in patients ages 70 and older who received a stent using endothelial progenitor cell capture technology. The stent accelerates the...

April 21, 2010 — A landmark clinical trial has begun in Europe to explore the safety and efficacy of a paclitaxel-eluting stent for the treatment of renal artery disease.

April 21, 2010 – A stent that captures endothelial progenitor cells is now combined with thin cobalt chromium stent struts with a low profile for greater flexibility and deliverability. The Genous...